Publications

NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.
J Natl Compr Canc Netw 2018 Feb;16(2):123-135
From Memorial Sloan Kettering Cancer Center; Mayo Clinic Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Fox Chase Cancer Center; UC San Diego Moores Cancer Center; The University of Texas MD Anderson Cancer Center; Vanderbilt-Ingram Cancer Center; Huntsman Cancer Institute at the University of Utah; University of Colorado Cancer Center; Stanford Cancer Institute; Dana-Farber/Brigham and Women's Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Fred & Pamela Buffett Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Duke Cancer Institute; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; University of Wisconsin Carbone Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Washington/Seattle Cancer Care Alliance; Moffitt Cancer Center; Roswell Park Comprehensive Cancer Center; University of Michigan Comprehensive Cancer Center; The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute; City of Hope Comprehensive Cancer Center; and National Comprehensive Cancer Network.

Variability in the Expression of Immunohistochemical Markers: Implications for Biomarker Interpretation in Cutaneous T-cell Lymphoma.
J Invest Dermatol 2017 Dec 13. Epub 2017 Dec 13.
Department of Dermatology, Stanford University School of Medicine, Palo Alto, California, USA; Stanford Cancer Institute, Stanford University School of Medicine, Palo Alto, California, USA. Electronic address:


Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors.
Cancer Cell 2017 Jul 15;32(1):27-41.e4. Epub 2017 Jun 15.
Center for Personal Dynamic Regulomes and Program in Epithelial Biology, Stanford University School of Medicine, CCSR 2155c, 269 Campus Drive, Stanford, CA 94305-5168, USA; Department of Dermatology, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address:


Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome.
J Neurooncol 2017 May 7;132(3):439-446. Epub 2017 Mar 7.
Division of Neuro-Oncology, Department of Neurology and Neurological Sciences, Stanford University, 875 Blake Wilbur Drive, CC 2221, Stanford, CA, 94305-5826, USA.


Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
J Clin Oncol 2015 Nov 20;33(32):3750-8. Epub 2015 Jul 20.
Youn H. Kim, Mahkam Tavallaee, Uma Sundram, Shufeng Li, Sima Rozati, Seema Nagpal, Michael Krathen, Sunil Reddy, Richard T. Hoppe, Annie Nguyen-Lin, Wen-Kai Weng, Randall Armstrong, and Ranjana H. Advani, Stanford University, Stanford, CA; Katrin A. Salva and Gary S. Wood, University of Wisconsin and William S. Middleton Memorial Veterans Hospital, Madison, WI; and Melissa Pulitzer and Steven M. Horwitz, Memorial Sloan Kettering Cancer Center, New York, NY.

Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.
J Clin Oncol 2015 Nov 5;33(32):3766-73. Epub 2015 Oct 5.
Julia J. Scarisbrick and Felicity Evison, University Hospital Birmingham, Birmingham; Richard Cowan, The Christie Hospital, Manchester; Stephen Morris and Sean J. Whittaker, St Thomas' Hospital, London, United Kingdom; H. Miles Prince and Robert Twigger, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Maarten H. Vermeer and Rein Willemze, Leiden University Medical Centre, Leiden, the Netherlands; Pietro Quaglino, Paolo Fava, and Milena Maule, University of Turin (Torino), Turin; Emilio Berti, Francesco Onida, and Laura Corti, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, University of Milano-Bicocca, Milan; Nicola Pimpinelli and Vieri Grandi, University of Florence, Florence; Alessandro Pileri and Annalisa Patrizi, University of Bologna, Bologna, Italy; Steven Horwitz and Christiane Querfeld, Memorial Sloan-Kettering Cancer Center, New York, NY; Pierluigi Porcu, Henry Wong, and Kelly Tyler, Ohio State University, Columbus, OH; Gary S. Wood, University of Wisconsin, Madison, WI; Francine Foss and Michael Girardi, Yale University, New Haven, CT; Joan Guitart, Timothy M. Kuzel, and Maria Estela Martinez-Escala, Northwestern University, Chicago, IL; Alain Rook and Ellen Kim, University of Pennsylvania, Philadelphia; PA; Christiane Querfeld, City of Hope Hospital, Duarte; Jinah Kim, Grant Ognibene, Shufeng Li, Mahkam Tavallaee, Richard T. Hoppe, and Youn H. Kim, Stanford University Medical Center, Stanford, CA; Rakhshandra Talpur and Madeleine Duvic, The University of Texas MD Anderson Cancer Center, Houston, TX; Rudolf Stadler and Rene Stranzenbach, Unit University Munster, Minden, Germany; Marie Beylot-Barry and Anne Pham-Ledard, Centre Hospitalier Universitaire Hospital de Bordeaux, Bordeaux; Martine Bagot, Laurence Michel, and Maxime Battistella, Hospital St Louis, Paris, France; Teresa Estrach, Hospital Clínico, University of Barcelona, Villarroel; Octavio Servitje and Cristina Muniesa,



Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders.
Am J Surg Pathol 2014 Sep;38(9):1203-11
Departments of *Pathology #Dermatology, Stanford University School of Medicine, Stanford †UCLA Medical Center, Los Angeles ‡San Diego Pathologists Medical Group, San Diego, CA §Department of Dermatology, Mayo Clinic, Jacksonville, FL ∥Department of Pathology, Massachusetts General Hospital, Boston, MA ¶Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.









The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.
Am J Hematol 2012 Apr 24;87(4):354-60. Epub 2012 Feb 24.
Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104 , USA.

Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations.
Clin Lymphoma Myeloma Leuk 2012 Feb 15;12(1):20-5. Epub 2011 Oct 15.
Department of Medicine, New York Presbyterian-Weil Cornell Medical Center, 1275 York Avenue, New York, NY 10021, USA.














Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma.
Blood 2007 Jun 20;109(11):4655-62. Epub 2007 Feb 20.
Multidisciplinary Cutaneous Lymphoma Program, Stanford Comprehensive Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA.

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.
J Natl Compr Canc Netw 2016 09;14(9):1067-79
From Memorial Sloan Kettering Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; The University of Texas MD Anderson Cancer Center; Massachusetts General Hospital Cancer Center; Stanford Cancer Institute; UCSF Helen Diller Family Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fox Chase Cancer Center; Huntsman Cancer Institute at the University of Utah; Mayo Clinic Cancer Center; Roswell Park Cancer Institute; University of Michigan Comprehensive Cancer Center; Duke Cancer Institute; Consultant; Dana-Farber/Brigham and Women's Cancer Center; Fred & Pamela Buffett Cancer Center; City of Hope Comprehensive Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; University of Colorado Cancer Center; Vanderbilt-Ingram Cancer Center; UC San Diego Moores Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Alabama at Birmingham Comprehensive Cancer Center; Moffitt Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; St. Jude Children's Research Hospital/University of Tennessee Health Science Center; and National Comprehensive Cancer Network.

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017.
J Natl Compr Canc Netw 2017 03;15(3):293-311
From The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Massachusetts General Hospital Cancer Center; Stanford Cancer Institute; UCSF Helen Diller Family Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Fox Chase Cancer Center; Huntsman Cancer Institute at the University of Utah; Mayo Clinic Cancer Center; Roswell Park Cancer Institute; University of Michigan Comprehensive Cancer Center; Duke Cancer Institute; Consultant; Dana-Farber/Brigham and Women's Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; City of Hope Comprehensive Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; University of Colorado Cancer Center; Vanderbilt-Ingram Cancer Center; UC San Diego Moores Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Alabama at Birmingham Comprehensive Cancer Center; Moffitt Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Fred & Pamela Buffett Cancer Center; and National Comprehensive Cancer Network.

OF